We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.95B
1-Year Est. Return 773.9%
This Fund
S&P 500
This Quarter Est. Return
+13.35%
1 Year Est. Return
+773.9%
3 Year Est. Return
+3,976.92%
5 Year Est. Return
+17,750.67%
10 Year Est. Return
+592,782.78%
AUM
$2.6B
AUM Growth
-$20.1M
Cap. Flow
-$117M
Cap. Flow %
-4.48%
Top 10 Hldgs %
41.28%
Holding
99
New
18
Increased
10
Reduced
56
Closed
6

Top Buys

Rank Stock Value
1
IMVT icon
Immunovant
IMVT
+$49.3M
2
ALXO icon
ALX Oncology
ALXO
+$38.2M
3
OMER icon
Omeros
OMER
+$28.6M
4
TRIL
Trillium Therapeutics Inc.
TRIL
+$24.9M
5
ZYME icon
Zymeworks
ZYME
+$20.6M

Top Sells

Rank Stock Value
1
PRNB
Principia Biopharma Inc. Common Stock
PRNB
+$95.1M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$30.8M
3
STSA
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
+$23M
4
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
+$20.6M
5
CCXI
ChemoCentryx, Inc.
CCXI
+$16.2M

Sector Composition

Rank Sector Weight
1 Healthcare 87.13%
2 Miscellaneous 12.87%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AUTL
76
Autolus Therapeutics
AUTL
$511M
$4.91M 0.19%
422,167
-57,821
-12% -$838K
KZR
77
DELISTED
Kezar Life Sciences
KZR
$4.51M 0.17%
93,180
-36,820
-28% -$1.76M
VSPRU
78
DELISTED
Vesper Healthcare Acquisition Corp. Unit
VSPRU
$4.1M 0.16%
+400,000
New +$4.1M
BCEL
79
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$4.1M 0.16%
293,500
-27,822
-9% -$415K
KDMN
80
DELISTED
Kadmon Holdings, Inc.
KDMN
$3.92M 0.15%
1,000,000
-800,000
-44% -$3.36M
EIGR
81
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$3.66M 0.14%
14,984
-8,349
-36% -$2.6M
TECX
82
Tectonic Therapeutic
TECX
$555M
$3.18M 0.12%
20,336
-6,129
-23% -$1.23M
GOSS icon
83
Gossamer Bio
GOSS
$66.2M
$3.08M 0.12%
3,105
-1,262
-29% -$1.34M
PANA.U
84
DELISTED
Panacea Acquisition Corp. Units, each consisting of one share of Class A common stock and one-third
PANA.U
$3M 0.12%
+250,000
New +$2.88M
CRDF icon
85
Cardiff Oncology
CRDF
$103M
$2.48M 0.1%
+175,000
New +$1.16M
ARNA
86
DELISTED
Arena Pharmaceuticals Inc
ARNA
$2.24M 0.09%
30,000
-45,000
-60% -$3M
DTIL icon
87
Precision BioSciences
DTIL
$181M
$2.13M 0.08%
11,551
– –
AMRN
88
Amarin Corp
AMRN
$296M
$1.26M 0.05%
15,000
-15,000
-50% -$1.8M
ORTX
89
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$1.05M 0.04%
25,665
– –
NKTR icon
90
Nektar Therapeutics
NKTR
$2.27B
$830K 0.03%
3,333
-5,000
-60% -$1.57M
NERV icon
91
Minerva Neurosciences
NERV
$173M
$759K 0.03%
29,852
-34,168
-53% -$924K
FATE icon
92
Fate Therapeutics
FATE
$289M
$600K 0.02%
15,000
-35,000
-70% -$1.22M
OTLKW
93
DELISTED
Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022
OTLKW
$54K ﹤0.01%
416,666
– –
BNR
94
Burning Rock Biotech
BNR
$139M
– –
-25,000
Closed -$6.75M
NXTC icon
95
NextCure
NXTC
$27.8M
– –
-57,831
Closed -$14.9M
XFOR icon
96
X4 Pharmaceuticals
XFOR
$344M
– –
-10,966
Closed -$1.76M
STSA
97
DELISTED
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
– –
-798,905
Closed -$23M
ARYBU
98
DELISTED
ARYA Sciences Acquisition Corp II Unit
ARYBU
– –
-400,000
Closed -$4.64M
PRNB
99
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
– –
-1,590,493
Closed -$95.1M
1 2 3
4

Similar funds

AHC
Adell Harriman & Carpenter Houston, Texas $1.95B AUM 52.72% 1-Year Est. Return
FFS
Founders Financial Securities Towson, Maryland $1.95B AUM 22.17% 1-Year Est. Return
GIP
Granite Investment Partners El Segundo, California $1.95B AUM 49.89% 1-Year Est. Return
SLF
Sun Life Financial Toronto, Ontario, Canada $1.95B AUM 25.88% 1-Year Est. Return
BFPW
BOK Financial Private Wealth Denver, Colorado $1.95B AUM 20.52% 1-Year Est. Return
MSA
MUFG Securities Americas New York $1.95B AUM 42.71% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return
GF
Greenhouse Funds Baltimore, Maryland $1.96B AUM 36.47% 1-Year Est. Return

Cormorant Asset Management's Q3 2020 Portfolio in Review

As of Q3 2020, Cormorant Asset Management held 99 positions worth $2.6B, down 0.77% from $2.62B the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Cormorant Asset Management withdrew a net $117M in Q3 2020, closing 6 positions and reducing 56 holdings. Its most notable exit was Principia Biopharma Inc. Common Stock, an estimated $95.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, up from 87% a quarter earlier, followed by Miscellaneous.

Against the trend, Cormorant Asset Management opened a new position in Immunovant worth $57.6M.

  • Cormorant Asset Management's largest Q3 2020 buy was Immunovant: 1,637,951 shares worth $57.6M.
  • Cormorant Asset Management added most to Omeros in Q3 2020, an estimated $28.6M increase.
  • Cormorant Asset Management's biggest Q3 2020 reduction was Mirati Therapeutics, Inc. Common Stock, cutting an estimated $30.8M.
  • Cormorant Asset Management fully exited Principia Biopharma Inc. Common Stock in Q3 2020, selling an estimated $95.1M.
  • Cormorant Asset Management's ten largest holdings make up 41% of its $2.6B portfolio in Q3 2020.
  • Cormorant Asset Management opened 18 new positions and closed 6 in Q3 2020.
  • Cormorant Asset Management's portfolio value fell 0.77% quarter-over-quarter to $2.6B.

Based on Cormorant Asset Management's 13F filing for Q3 2020, filed 16 Nov 2020.